Medigene is developing Living Immunotherapies, with the goal of providing revolutionizing cancer treatments that offer a higher quality of life for patients.
We aim to enter strategic partnerships with interested parties to share the transformative potential of cancer immunotherapies with partners who truly believe in innovation.
Please contact our business development team if you are interested in discussing our clinical programs or want to develop new innovative immunotherapies based on our technologies to optimally tackle specific tumor types.
Developmental and Commercial Partnerships
In order to change the paradigm of cancer treatment, Medigene seeks partnerships with other leaders in the field to exploit the full potential of our immunotherapy technology platforms. Therefore, we are already collaborating with industry leaders:
Université de Montréal/ IRICoR, Canada
In January 2020, Medigene entered into a research collaboration on novel cancer antigens for highly specific immunotherapies with the Université de Montréal (UdeM) and IRICoR, a pan-Canadian drug discovery research commercialization center. UdeM's research team, led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer (IRIC), will provide Medigene with tumor-specific antigens (TSAs) which they discovered using their proprietary platform, as novel targets for various cancer indications, particularly for solid tumors. Under the terms of the agreement, Medigene will evaluate a number of proprietary TSA targets provided by UdeM through IRICoR, and will receive an option to exercise an exclusive and worldwide license to develop and commercialize T cell receptors (TCRs) against up to 5 of these novel cancer antigens.
In April 2019, Medigene has entered into a multi-program license and collaboration agreement for its T cell receptor (TCR)-modified T cell therapies and a dendritic cell (DC) vaccine with Cytovant Sciences, an affiliate of the US biopharmaceutical company Roivant Sciences Ltd. Cytovant was founded by the Roivant Group as a biopharmaceutical company focused on developing and commercializing innovative cellular therapeutics in Asia.
bluebird bio, Inc., USA
In September 2016, bluebird bio and Medigene established a strategic T cell receptor (TCR) alliance in cancer immunotherapy. The strategic research and development collaboration and licensing agreement encompasses T cell receptor (TCR)- immunotherapies against six targets (after an extension of the contract in May 2018). Under the terms of the agreement, Medigene will be responsible for the generation and delivery of the TCR-Ts using its TCR-isolation and characterization platform. Following collaborative preclinical development, bluebird bio will assume sole responsibility for the clinical development and commercialization of the TCR-T product candidates and will receive an exclusive license for the intellectual property covering the resulting TCR-Ts.
BioNTech IMFS GmbH , Germany
Medigene has signed an agreement with the contract manufacturer BioNTech IMFS GmbH (former EUFETS GmbH) in February 2016 for the production and delivery of viral vectors and cellular therapeutic products. BioNTech IMFS GmbH is an experienced contract manufacturing organization (CMO) that will take over further process development tasks and vector optimization processes, the establishment of different cell banks, and the batch production of viral vectors for Medigene's T cell receptor (TCR)- based cancer therapies. In addition, BioNTech IMFS serves as contract manufacturer for patient-individualized TCR-T therapeutics for use in clinical studies.
PHIO Pharmaceuticals Corp.
Medigene has entered a research collaboration with PHIO Pharmaceuticals Corp. (former RXi Pharmaceuticals Corporation) and Helmholtz Zentrum München to design and develop novel candidates for the use of INTASYLTM compounds in adoptive cell therapy to enhance immune cell function. Medigene contributes expertise regarding clinical development as well as proprietary research material and has an option to an exclusive license for the clinical and/or commercial exploitation of the potential immune cell enhancers against certain fee payments.
In order to support the development of our research projects, we have built an international scientific network through partnerships. Academic and clinical contacts and collaborations have been established with leading hospitals and institutions in Europe and in North America, such as:
Charité - Universitätsmedizin Berlin (Charité), Germany:
Max-Delbrück-Centre for Molecular Medicine in the Helmholtz-Gemeinschaft (MDC)
University Hospital Oslo, Norway
RhuDex®: Outlicensed to Dr. Falk Pharma GmbH
RhuDex® is an oral, disease modifying agent to treat autoimmune diseases. It is a CD80 antagonist that blocks undesired T-cell activation and production and therefore has both an immune-modulating and anti-inflammatory effect. The safety and tolerability of RhuDex® have been demonstrated in a number of Phase I clinical trials. Medigene has successfully completed a pilot Phase IIa trial in the indication rheumatoid arthritis. In 2013, Medigene outlined preparations for a further clinical development of RhuDex® in the indication of primary biliary cirrhosis (PBC).
In March 2014, Medigene signed a license agreement with the pharmaceutical company Dr. Falk Pharma GmbH, Freiburg, for the development and marketing rights to RhuDex® for hepatology and gastroenterology indications. Falk Pharma will assume responsibility and all costs relating to the clinical development and marketing of RhuDex® in these therapeutic areas.
Falk Pharma has initially concentrated on development in primary biliary cirrhosis (PBC). Medigene retains the rights for RhuDex® in rheumatoid arthritis, psoriasis and other autoimmune diseases.